{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:15:20Z","timestamp":1778868920274,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K21951"],"award-info":[{"award-number":["24K21951"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22fk0108523"],"award-info":[{"award-number":["22fk0108523"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtm.2025.101459","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T20:15:18Z","timestamp":1743538518000},"page":"101459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants"],"prefix":"10.1016","volume":"33","author":[{"given":"Takaaki","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariko","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoaki","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-3102","authenticated-orcid":false,"given":"Toru","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-1319","authenticated-orcid":false,"given":"Atsushi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101459_bib1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.chom.2021.06.016","article-title":"The success of SARS-CoV-2 vaccines and challenges ahead","volume":"29","author":"Subbarao","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.omtm.2025.101459_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101459_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2313","article-title":"Covid-19 vaccines and variants of concern: A review","volume":"32","author":"Hadj Hassine","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omtm.2025.101459_bib4","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","volume":"24","author":"Machkovech","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101459_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2025.101459_bib6","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"Cevik","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.omtm.2025.101459_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2025.101459_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-061323-073837","article-title":"Lessons from the Use of Monoclonal Antibodies to SARS-CoV-2 Spike Protein During the COVID-19 Pandemic","volume":"76","author":"Casadevall","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v16020184","article-title":"Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness","volume":"16","author":"Liu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2025.101459_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib12","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S1473-3099(23)00588-1","article-title":"Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses","volume":"23","author":"Sheward","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101459_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.tips.2022.06.011","article-title":"Engineering ACE2 decoy receptors to combat viral escapability","volume":"43","author":"Arimori","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib14","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","article-title":"Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2","volume":"12","author":"Higuchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101459_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2623","article-title":"An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models","volume":"15","author":"Urano","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7737","article-title":"An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo","volume":"14","author":"Ikemura","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101459_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216109","article-title":"An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib19","article-title":"Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters","volume":"2","author":"Piepenbrink","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2022.11.006","article-title":"Inhalable neutralizing antibodies - promising approach to combating respiratory viral infections","volume":"44","author":"Chow","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122042","article-title":"Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices","volume":"624","author":"Saha","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jamp.2022.0020","article-title":"Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies","volume":"36","author":"Brun","year":"2023","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.omtm.2025.101459_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105987","article-title":"Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19","volume":"167","author":"Ari","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.addr.2021.02.016","article-title":"Pharmaceutical protein solids: Drying technology, solid-state characterization and stability","volume":"172","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2025.101459_bib25","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","article-title":"Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101459_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101459_bib27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101459_bib28","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1208\/s12249-018-1023-2","article-title":"Spray-Freeze Drying: a Suitable Method for Aerosol Delivery of Antibodies in the Presence of Trehalose and Cyclodextrins","volume":"19","author":"Pouya","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.omtm.2025.101459_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40005-022-00610-x","article-title":"Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals","volume":"53","author":"Emami","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.omtm.2025.101459_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114527","article-title":"Recent developments in lactose blend formulations for carrier-based dry powder inhalation","volume":"189","author":"Hebbink","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2025.101459_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123272","article-title":"Enhanced powder dispersion of dual-excipient spray-dried powder formulations of a monoclonal antibody and its fragment for local treatment of severe asthma","volume":"644","author":"Pan","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib32","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.1208\/pt060243","article-title":"Cyclodextrins in drug delivery: an updated review","volume":"6","author":"Challa","year":"2005","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.omtm.2025.101459_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119564","article-title":"Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders","volume":"586","author":"Wanning","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejpb.2019.09.014","article-title":"The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes","volume":"144","author":"Mah","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.omtm.2025.101459_bib35","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.xphs.2024.06.018","article-title":"Leucine as a moisture-protective excipient in spray-dried protein\/trehalose formulation","volume":"113","author":"Zhang","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41591-020-01227-z","article-title":"Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics","volume":"27","author":"Muus","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib37","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101459_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtm.2025.101459_bib39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtm.2025.101459_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2013.08.003","article-title":"Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus","volume":"100","author":"He","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtm.2025.101459_bib41","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Leyva-Grado","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.omtm.2025.101459_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28721","article-title":"M2e-specific antibodies protect against influenza PR8 virus in an isotype and route dependent manner","volume":"95","author":"Sun","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omtm.2025.101459_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683902","article-title":"Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis","volume":"12","author":"Jacque","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101459_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2260040","article-title":"Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy","volume":"19","author":"Focosi","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtm.2025.101459_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/10837450.2018.1507039","article-title":"Application of disaccharides alone and in combination, for the improvement of stability and particle properties of spray-freeze dried IgG","volume":"24","author":"Daneshmand","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.omtm.2025.101459_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejps.2018.04.013","article-title":"Effect of amino acids on the stability of spray freeze-dried immunoglobulin G in sugar-based matrices","volume":"119","author":"Emami","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib47","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/jps.10204","article-title":"Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability","volume":"91","author":"Sonner","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2017.07.033","article-title":"Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation","volume":"530","author":"Li","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1208\/s12248-015-9802-0","article-title":"De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products","volume":"17","author":"Leung","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2025.101459_bib50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1208\/s12249-020-01757-2","article-title":"Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers","volume":"21","author":"ElKasabgy","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.omtm.2025.101459_bib51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s11095-015-1838-4","article-title":"Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device","volume":"33","author":"Otake","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtm.2025.101459_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba2927","article-title":"Citrullinated vimentin mediates development and progression of lung fibrosis","volume":"13","author":"Li","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101459_bib53","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.drudis.2021.04.009","article-title":"Leucine as an excipient in spray dried powder for inhalation","volume":"26","author":"Alhajj","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtm.2025.101459_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5635010","article-title":"Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering","volume":"2018","author":"Mehta","year":"2018","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.omtm.2025.101459_bib55","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1080\/10408398.2018.1431202","article-title":"Chemical methods and techniques to monitor early Maillard reaction in milk products; A review","volume":"59","author":"Aalaei","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.omtm.2025.101459_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100018","article-title":"Engineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection","volume":"1","author":"Nishioka","year":"2025","journal-title":"Cell Biomaterials"},{"key":"10.1016\/j.omtm.2025.101459_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00621-23","article-title":"Sequence basis for selectivity of ephrin-B2 ligand for Eph receptors and pathogenic henipavirus G glycoproteins","volume":"97","author":"Narayanan","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101459_bib58","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1074\/jbc.RA120.013887","article-title":"Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag","volume":"295","author":"Ozono","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101459_bib59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s42003-022-03427-4","article-title":"SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication","volume":"5","author":"Miyamoto","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtm.2025.101459_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109014","article-title":"Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction","volume":"35","author":"Torii","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101459_bib61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jviromet.2005.05.005","article-title":"Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression","volume":"128","author":"Biacchesi","year":"2005","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.omtm.2025.101459_bib62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/acs.molpharmaceut.8b00502","article-title":"Naked pDNA Inhalation Powder Composed of Hyaluronic Acid Exhibits High Gene Expression in the Lungs","volume":"16","author":"Ito","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124425","article-title":"Cryomilled electrospun nanofiber mats containing d-mannitol exhibit suitable for aerosol delivery of proteins","volume":"661","author":"Ito","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2025.101459_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3827","article-title":"A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection","volume":"8","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2025.101459_bib65","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101459_bib66","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias","volume":"155","author":"Blinova","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtm.2025.101459_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107530","article-title":"Contractility assessment using aligned human iPSC-derived cardiomyocytes","volume":"128","author":"Satsuka","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.omtm.2025.101459_bib68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yjmcc.2014.09.010","article-title":"Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology","volume":"77","author":"Hayakawa","year":"2014","journal-title":"J. Mol. Cell. Cardiol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:55:17Z","timestamp":1778867717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2329050125000543"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101459","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101459"}}